Highest-materiality recent filing
IO Biotech files Chapter 7 bankruptcy, ceases operations, all directors and employees terminated
Filed Chapter 7 bankruptcy petition in Delaware on March 31, 2026; company ceases operations.
IO Biotech receives Nasdaq MVLS deficiency notice; 180 days to comply
Notice received Feb 12, 2026; MVLS below $50M for 30 consecutive business days.
IO Biotech explores strategic alternatives, cuts workforce, CMO departs, hires Raymond James
Retained Raymond James as exclusive financial advisor to assist in exploration of strategic alternatives.
IO Biotech to explore strategic alternatives including merger, sale, or liquidation
Company to evaluate merger, business combination, sale of assets, or liquidation and dissolution.
IO Biotech receives Nasdaq bid price deficiency notice; has until June 16, 2026 to regain compliance
Nasdaq notified IO Biotech on Dec 17, 2025 that bid price < $1.00 for 30 consecutive days.
IO Biotech Q3: Phase 3 melanoma trial narrowly misses PFS endpoint; cash $30.7M, runway to Q1 2026
Phase 3 IOB-013 trial in advanced melanoma showed PFS improvement but narrowly missed statistical significance; FDA meeting in December for new registrational trial design.
FDA advises IO Biotech not to submit BLA for Cylembio; workforce cut by ~50%
FDA recommends against BLA submission based on IOB-013 trial data (PFS improved but missed statistical significance).
IO Biotech Q2 net loss $26.2M; Ph3 Cylembio trial misses PFS endpoint, plans FDA meeting fall 2025
Phase 3 trial of Cylembio+Keytruda in advanced melanoma showed clinical improvement in PFS but narrowly missed statistical significance.
IO Biotech Phase 3 Cylembio trial misses statistical significance; PFS improved 19.4 vs 11.0 mo
Primary endpoint PFS HR=0.77 (CI 0.58-1.00), p=0.056, missed significance threshold p≤0.045.
IO Biotech draws €12.5M Tranche B from EIB, issues warrant for 4.22M shares at $1.3159
Satisfied conditions to draw €12.5M second tranche (Tranche B) from EIB loan facility of up to €57.5M.
IO Biotech Q1 net loss $22.4M; Phase 3 melanoma vaccine readout on track for Q3 2025
Net loss of $22.4M in Q1 2025 vs $19.5M in Q1 2024; R&D expenses rose to $16.4M.
IO Biotech issues warrant to EIB for up to 5.6M shares at $0.8891; €10M draw expected May 6
Issued Tranche A Warrant to EIB to purchase up to 5,623,664 shares of common stock at $0.8891 per share.
IO Biotech expects Phase 3 PFS readout in Q3 2025; cash of $60M extends runway to Q2 2026
Phase 3 trial (advanced melanoma) PFS primary endpoint readout delayed to Q3 2025; BLA submission still planned by year-end 2025.
IO Biotech receives Nasdaq bid price deficiency notice; stock at risk of delisting
Nasdaq notice on Dec 26, 2024: common stock bid price below $1.00 for 30 consecutive days.
IO Biotech secures up to €57.5M EIB debt facility; extends cash runway into Q2 2026
Total committed tranches of €37.5M (Tranche A €10M, B €12.5M, C €15M) plus €20M uncommitted accordion.
IO Biotech Q3 net loss $24.0M; Phase 3 melanoma trial on track for PFS in H1 2025
Net loss $24.0M for Q3 2024 vs $21.7M in Q3 2023; R&D expenses $20.2M up from $17.7M.
IO Biotech Phase 3 trial IDMC recommends continuation; PFS endpoint expected H1 2025
IDMC recommends Phase 3 trial of IO102-IO103 + pembrolizumab continue without modifications after interim analysis.
IO Biotech Q2 net loss $20.7M; cash runway into Q4 2025; Phase 3 interim analysis expected Q3 2024
Net loss of $20.7M for Q2 2024 vs $21.2M in Q2 2023; R&D expenses $15.8M.
IO Biotech Q1 2024 net loss $19.5M; Phase 3 melanoma interim ORR data expected Q3 2024
Net loss $19.5M for Q1 2024 vs $17.0M in Q1 2023; R&D expenses $14.3M (up from $11.9M).
Net loss $26.2M in Q4 2023 vs $20.1M YoY; R&D expenses $21.8M on Phase 3 trial costs.
IO Biotech Q3 net loss $21.7M, cash $165.5M; Phase 3 melanoma trial fully enrolled
Net loss $21.7M in Q3 2023 vs $15.7M Q3 2022; R&D expenses $17.7M (up from $10.0M) driven by Phase 3 trial.
Net loss of $21.2M (vs $18.5M Q2 2022); R&D spend $16.5M on Phase 3 trial execution.
IO Biotech raises ~$75M in private placement; cash runway extended to Q4 2025
Gross proceeds of ~$75.1M from sale of 37.1M shares and warrants at $2.025 combined price.
IO Biotech hits 225-patient enrollment milestone in Phase 3 melanoma trial; expanded to 380
225 patients randomized in Phase 3 trial of IO102-IO103 + pembrolizumab for advanced melanoma.
Net loss $17.0M for Q1 2023, nearly flat vs $17.2M in Q1 2022.
IO Biotech reports 2022 net loss of $71.5M; cash runway through Q3 2024
Net loss $71.5M for 2022 vs $67.9M for 2021; Q4 net loss $20.1M vs $21.3M.
IO Biotech launches $19.5M ATM equity program with Cowen, up to $75M total
Filed prospectus supplement for at-the-market offering of common stock up to $19.5 million.
IDMC recommends Phase 3 melanoma trial continue without changes; enrolling at >80 sites globally.
Net loss $15.7M (vs $4.5M in Q3 2021); R&D expenses $10.0M (up from $4.1M) driven by Phase 3 trial costs.
IO Biotech appoints Amy Sullivan as CFO effective Oct 15, 2022
Amy Sullivan, 53, appointed CFO and Principal Financial Officer, effective October 15, 2022.
IO Biotech reports Q2 net loss of $18.5M; cash $170.1M to fund data readouts into mid-2024
Net loss $18.5M for Q2 2022 vs $38.4M in Q2 2021, driven by higher R&D and G&A costs.
IO Biotech Q1 2022 net loss $17.2M; cash $187.9M; Phase 2 trial initiated
Net loss of $17.2M for Q1 2022 vs $3.7M in Q1 2021; R&D expenses $10.3M (up $7.5M).
IO Biotech reports FY2021 net loss of $67.9M; cash of $211.5M supports operations into mid-2024
Net loss $67.9M in FY2021 vs $12.0M in FY2020; R&D expenses rose to $30.2M from $8.5M.
On April 24, 2024, Jack Nielsen, a member of the board of directors (the “Board”) of IO Biotech, Inc. (the “Company”), notified the Company of his resignation from the Board, effective that same date.
On November 9, 2023, the Company increased the size of the Board from seven to eight directors, and appointed Helen Collins, M.D. as a Class II director of the Company to fill the vacancy, effective as of that same date.
On August 7, 2023, Priyanka Belawat, a member of the Board of Directors of the Company, notified the Company of her resignation from the Board, effective that same date.
On August 8, 2023, the Company appointed Heidi Hunter as a Class II director of the Company, effective as of August 11, 2023.
On July 15, 2023, IO Biotech, Inc. (the “Company”) appointed Qasim Ahmad, M.D. as the Company’s Chief Medical Officer, effective as of that same date.
Dr. Ehrnrooth will now transition from her role as Chief Medical Officer to Senior Clinical Advisor, effective immediately.
On April 17, 2023, Vanessa Malier, a member of the board of directors (the “Board”) of IO Biotech, Inc. (the “Company”), notified the Company of her resignation from the Board, effective that same date.
On October 13, 2022, IO Biotech, Inc. (the “Company”) appointed Amy Sullivan, 53, as the Company’s Chief Financial Officer, effective as of October 15, 2022.
On May 12, 2022, the Company appointed Brian Burkavage, 39, the Company’s Vice President of Finance, as its Chief Accounting Officer, effective immediately.
On May 9, 2022, IO Biotech, Inc. (the “Company”) and Keith Vendola, Chief Financial Officer of the Company, have terminated Mr. Vendola’s employment with the Company by mutual agreement, effective immediately.
On April 12, 2022, Dr. Claus Andersson, a director of the board of directors (the “Board”) of the IO Biotech, Inc. (the “Company”), notified the Company that he will not stand for reelection at the Company’s 2022 annual meeting of stockholders.
On the same date, Dr. Emmanuelle Coutanceau, a director of the Board, notified the Company that she will not stand for reelection at the Company’s 2022 annual meeting of stockholders.
Max materiality 1.00 · Median 0.60 · Most common event other_material